#United States #New York #Securities Fraud #Rosen Law Firm #Ultragenyx

Ultragenyx Pharmaceutical Inc. Under Legal Scrutiny: Join the Class Action

Investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) are being called to participate in a class action lawsuit led by the Rosen Law Firm, a firm well-regarded for advocating investor rights. The lawsuit pertains to claims made during a specific period from August 3, 2023, to December 26, 2025, during which investors purchased common stock from the company.

Reasons Behind the Lawsuit

The allegations suggest that Ultragenyx provided misleading information concerning its drug setrusumab (UX143), intended for treating Osteogenesis Imperfecta (OI). The firm claimed that setrusumab could significantly reduce annual fracture rates in patients, a statement that investors relied upon when purchasing shares. However, evidence later suggested that the confidence in setrusumab's performance and study designs was unfounded, as the increase in bone density did not equate to reduced fractures—a fact that was allegedly concealed from investors.

Steps for Affected Investors

If you bought stock in Ultragenyx during the identified class period, you might be entitled to compensation. Investors are encouraged to act swiftly as the deadline to serve as lead plaintiff is April 6, 2026. To join the class action, affected individuals can visit the Rosen Law Firm’s website or contact them directly via phone or email for further guidance.

The Track Record of Rosen Law Firm

Rosen Law Firm has demonstrated a strong track record in leading securities class actions, having secured one of the largest settlements against a Chinese company and consistently ranking high in the number of class action settlements. The firm's experience includes a significant recovery amount of over $438 million in 2019 for their clients. The founders and attorneys are recognized figures in the legal field, reinforcing trust for potential plaintiffs seeking legal representation.

Understanding Your Legal Rights

It is important for investors to understand that until a class is certified, they are not represented by counsel unless they explicitly choose to engage one. You may opt to join the lawsuit to recover potential losses tied to the alleged fraud or decide to remain an absent class member without immediate actions.

This case provides a critical opportunity for investors who feel misled during their investment decisions regarding Ultragenyx. Regular updates regarding the class action process will be made available through the Rosen Law Firm's social media platforms, ensuring transparency and accessibility for all involved parties.

Conclusion

The ongoing class action against Ultragenyx serves as a reminder of the importance of due diligence when investing, particularly in the pharmaceutical sector where outcomes can significantly influence stock prices. Investors should stay informed about their rights and options, potentially recovering losses incurred during the alleged misconduct period. Those affected should seek to join the class action promptly to ensure their interests are represented.